Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.50 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146456 | 0.90 | CCR2 (0.62) | CCR2 | |
| SCHEMBL13146503 | 0.89 | PGAM1 (0.53) | CCR2PGAM1MMP7ACLYTSHR | |
| SCHEMBL13146515 | 0.88 | LMNA (0.55) | CCR2PGAM1ACLY | |
| SCHEMBL13146485 | 0.87 | ACLY (0.60) | CCR2ACLYTSHR | |
| SCHEMBL13146487 | 0.83 | LMNA (0.66) | CCR2PGAM1 | |
| SCHEMBL3083483 | 0.80 | CCR9 (0.65) | CCR2 | |
| SCHEMBL1104715 | 0.77 | CCR2 (0.67) | CCR2ACLY | |
| SCHEMBL305754 | 0.77 | CYP2C9 (0.66) | CCR2PGAM1TSHR | |
| SCHEMBL2537160 | 0.75 | CCR9 (0.67) | — | |
| SCHEMBL3091955 | 0.75 | TSHR (0.60) | CCR2PGAM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | CCR2 1/4885PGAM1 4183/4885MEP1B 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.